{"product_id":"si-bone-swot-analysis","title":"SI-Bone SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSI-Bone’s innovative sacroiliac fusion devices and growing clinical evidence position it well in a niche market, but reimbursement pressures and competitive entrants pose risks; discover comprehensive strengths, weaknesses, opportunities, and threats with our full SWOT analysis—purchase the complete report for an editable, research-backed Word and Excel package to support investment, strategy, or clinical commercialization decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Leadership in SI Joint Fusion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, SI-BONE holds the dominant market share in sacroiliac (SI) joint fusion—about 65% global share by procedures—with its proprietary iFuse Implant System, driving $210 million revenue in FY 2024 and projected $255 million for 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Clinical Data and Peer-Reviewed Evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSI-Bone’s core advantage is deep clinical validation: over 100 peer-reviewed publications and multiple prospective studies showing \u0026gt;80% sustained pain reduction at 2+ years, which by end-2025 creates a high barrier to entry for smaller rivals lacking long-term safety\/efficacy data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSI-BONE holds a broad patent portfolio covering design, materials, and surgical methods for the iFuse system and successors (iFuse-3D, iFuse-TORQ), with key patents extending into the mid-2020s and several through 2030+, creating a legal moat against generics. This protection supported a 2024 average selling price premium ~15–25% versus competitive SI joint implants. It lets SI-BONE defend margins—gross margin was 71% in FY2024—and sustain royalty\/licensing leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Specialized Sales and Training Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company has built a dedicated direct sales force and a surgeon training program widely viewed as best-in-class, supporting scale and adoption of the iFuse system.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 SI-BONE had trained over 3,200 surgeons, creating a loyal user base that drives high procedural volumes and repeat hospital procurement.\u003c\/p\u003e\n\u003cp\u003eThis training focus correlates with consistent outcomes and helped lift 2024 procedure-related revenue to ~$180m, improving per-procedure margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3,200+ surgeons trained by 2025\u003c\/li\u003e\n\u003cli\u003eDirect sales force = faster hospital access\u003c\/li\u003e\n\u003cli\u003eHigher procedure volume → better margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFavorable Reimbursement Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYears of advocacy and clinical data have secured broad private-payer and Medicare coverage for SI-BONE sacroiliac (SI) fusion in the US; CMS added clear coding and Medicare local coverage determinations by 2024–2025, easing access.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025, SI fusion is well-coded (CPT\/ICD crosswalks) and reimbursed—typical facility reimbursement grew ~12% 2021–2024—lowering patient out-of-pocket costs and provider billing friction.\u003c\/p\u003e\n\u003cp\u003eThis stable reimbursement pathway supports steady revenue growth and faster outpatient migration: SI-BONE reported outpatient procedure mix rising to ~45% by 2024, increasing margin potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare + major private payers: broad coverage\u003c\/li\u003e\n\u003cli\u003eCoding clarity achieved by 2024–2025\u003c\/li\u003e\n\u003cli\u003eFacility reimbursements up ~12% (2021–2024)\u003c\/li\u003e\n\u003cli\u003eOutpatient mix ~45% by 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiFuse: 65% SI‑fusion share, $210M FY24 revenue, $255M est 2025, 100+ studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiFuse leads SI‑fusion with ~65% global procedure share, FY2024 revenue $210M and 2025 est $255M; 3,200+ surgeons trained by 2025. Over 100 peer‑reviewed studies show \u0026gt;80% pain reduction at 2+ years; gross margin 71% (FY2024). Medicare\/private coverage, coding clarity by 2024–2025, outpatient mix ~45% (2024), facility reimbursement +12% (2021–2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal share\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue FY2024\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue 2025 est\u003c\/td\u003e\n\u003ctd\u003e$255M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeons trained\u003c\/td\u003e\n\u003ctd\u003e3,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvidence\u003c\/td\u003e\n\u003ctd\u003e100+ pubs; \u0026gt;80% pain ↓ at 2+ yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e71%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient mix 2024\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility reimbursement change\u003c\/td\u003e\n\u003ctd\u003e+12% (2021–2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of SI-Bone, highlighting internal strengths and weaknesses alongside external opportunities and threats to assess its competitive position and strategic growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a succinct SWOT snapshot of SI-Bone to quickly pinpoint strategic strengths, weaknesses, opportunities, and threats for fast decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Concentration and Revenue Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSI-BONE derives about 80–90% of 2024 revenue from the iFuse product family, leaving limited diversification; that concentration raises exposure if a clinical setback, device recall, or a payer reimbursement cut hits the SI joint market.\u003c\/p\u003e\n\u003cp\u003eInvestors compare this to medtech peers with broader portfolios; a single competitive breakthrough or regulatory change in the SI joint space could materially reduce annual sales and earnings, increasing valuation multiple volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operating Expenses and Path to Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpsi-bone continued to report gaap losses in as sg remained high through nine months ended sep keeping operating margins negative despite year-over-year revenue growth. the company surgeon training programs and a field sales team drove elevated customer-acquisition costs which stayed above industry medtech averages near per new surgeon. analysts warn sustained at of will delay consistent profitability into unless cac or fall.\u003e\n\u003c\/psi-bone\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of the Surgical Procedure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhile iFuse is minimally invasive, it needs a specific surgical skill set and shows a learning curve—studies report initial procedure times 20–35% longer and higher early complication rates in first 20 cases per surgeon.\u003c\/p\u003e\n\u003cp\u003eThis complexity slows adoption in rural and community hospitals; 2024 Medicare claims show 65% of iFuse procedures concentrated in top 20% of centers.\u003c\/p\u003e\n\u003cp\u003ePerceived difficulty caps short-term TAM growth, potentially trimming addressable cases by ~10–15% until wider training is achieved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Revenue Concentration in North America\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa significant portion of si-bone revenue product sales from the united states exposing company to shifts in u.s. medicare policy and reimbursement rates.\u003e\n\u003cpinternational expansion shows progress but as of q3 european and asian markets account for under sales lack equivalent reimbursement pathways limiting diversification.\u003e\n\u003cpthis concentration increases sensitivity to u.s. economic cycles regulatory changes and single-market payer decisions raising revenue volatility risk.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~86% US product sales (2024)\u003c\/li\u003e\n\u003cli\u003eEurope + Asia \u0026lt;15% of sales (Q3 2025)\u003c\/li\u003e\n\u003cli\u003eDependence on US reimbursement policy\u003c\/li\u003e\n\u003cli\u003eHigher revenue volatility from single-market exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pinternational\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Elective Procedure Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSI-Bone revenue is sensitive because SI joint fusion is elective and drops when hospitals cut staffing or patients defer care; during COVID-19 Q2 2020 elective surgeries plunged ~48% and SI-Bone reported GAAP revenue fell 36% YoY in that period, showing exposure to procedure delays.\u003c\/p\u003e\n\u003cp\u003eMacroeconomic slowdowns or outbreaks can postpone procedures, disrupting quarterly targets and tying performance to surgical ecosystem capacity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElective designation → demand swings\u003c\/li\u003e\n\u003cli\u003eQ2 2020 elective surgeries −48%\u003c\/li\u003e\n\u003cli\u003eSI-Bone Q2 2020 revenue −36% YoY\u003c\/li\u003e\n\u003cli\u003eRevenue linked to hospital staffing, patient willingness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSI‑Bone risk: iFuse concentration, US‑centric sales \u0026amp; costly adoption hurt margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration risk: 80–90% revenue from iFuse (2024), ~86% US sales, Europe+Asia \u0026lt;15% (Q3 2025), so single-market\/reimbursement moves heavily affect revenue; GAAP losses persisted as SG\u0026amp;A hit $76.4M through Sep 30, 2025, keeping margins negative; adoption limited by surgeon learning curve (20–35% longer times first 20 cases) and elective-procedure sensitivity (Q2 2020 elective surgeries −48%, SI-Bone revenue −36% YoY).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eiFuse share of revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e80–90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS product sales (2024)\u003c\/td\u003e\n\u003ctd\u003e~86%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl sales (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A (9M Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e$76.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure learning curve\u003c\/td\u003e\n\u003ctd\u003e20–35% longer (first 20 cases)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElective surgery shock (Q2 2020)\u003c\/td\u003e\n\u003ctd\u003e−48% cases; SI-Bone rev −36% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eSI-Bone SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is not a sample but the real, editable analysis you'll download post-purchase. Buy now to unlock the complete, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752549691769,"sku":"si-bone-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/si-bone-swot-analysis.png?v=1772242277","url":"https:\/\/matrixbcg.com\/products\/si-bone-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}